Second-line treatment of ovarian cancer with single-agent gemcitabine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Second-line treatment of ovarian cancer with single-agent gemcitabine

Published:2002-02 Issue:1 Volume:29 Page:9-10
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Markman Maurie

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference9 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

2. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results;Piccart;J Natl Cancer Inst,2000

3. Second-line treatment of ovarian cancer;Markman;Oncologist,2000

4. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer;Rothenberg;Ann Oncol,1996

5. Gemcitabine: A cytidine analogue active against solid tumors;Hui;Am J Health Syst Pharm,1997

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Patient with Recurrent Ovarian Cancer in Whom Kamikihito was Effective for Thrombocytopenia Induced by GEM Monotherapy;Kampo Medicine;2015

2. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors;Investigational New Drugs;2012-07-31

3. Multicenter Phase 2 Study of Combined Gemcitabine and Epirubicin as Second-Line Treatment for Patients With Advanced Ovarian Cancer;International Journal of Gynecologic Cancer;2010-07

4. A phase I study of topotecan and gemcitabine in advanced solid tumors;Investigational New Drugs;2010-06-25

5. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers;Journal of Obstetrics and Gynaecology Research;2010-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3